Etripamil (MSP-2017) 是一种短效的、L-型 钙通道 拮抗剂，能用于阵发性室上性心动过速 (PSVT) 的研究。Etripamil (MSP-2017) 通过钙离子慢通道抑制钙离子内流，从而减缓房室结传导，延长房室结不应期。
| Cas No. | 1593673-23-4 |
| 别名 | MSP-2017; (-)-MSP-2017 |
| 分子式 | C27H36N2O4 |
| 分子量 | 452.59 |
| 溶解度 | Ethanol : 120 mg/mL (265.14 mM; Need ultrasonic) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Etripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist, can be used for the research of Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil (MSP-2017) slows atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells[1][2]. [1]. Stambler BS, et al. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31;72(5):489-497.
[2]. Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia. |
